<DOC>
	<DOCNO>NCT02005458</DOCNO>
	<brief_summary>This study examine dose YPEG-rhG-CSF , once-per-cycle , similar efficacy safety , compare PEG-rhG-CSF , once-per-cycle , chemotherapy-induced neutropenia</brief_summary>
	<brief_title>Safety Efficacy YPEG-rhG-CSF Cancer Patients Receiving Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<criteria>Diagnosis nonsmall cell lung cancer Breast cancer , adequate carboplatin combine taxol cyclophosphamide combine pharmorubicin chemotherapy Karnofsky Score ≥ 70 Life Expectancy &gt; 3 month Age : 18～70yrs . Peripheral blood test : WBC≥3.5×106/mm3 , PLT≥100×106/mm3 , ANC≥1.5×106/mm3 ; Normal bone marrow function ; Bone marrow biopsy show active hematopoietic without cancer cell . Normal coagulation function , evidence hemorrhage tendency . No exit disease condition may influence drug absorption , distribution , metabolism , excretion . Adequate liver , cardiac , kidney function . Indicators liver function test ≤ 2.5ULN , Indicators kidney function test ≤ 1ULN Understand voluntarily sign informed consent form . Pregnant lactating female Evidence tumor metastasis bone marrow Lack insight due tumor metastasis central nervous system Prior bone marrow transplant stem cell transplant Infective symptom enrollment study Other malignancy history Known hypersensitivity component drug ( e.g . rhGCSF ) administer Subject enrol investigational drug device trial within 3 month inform consent date Drug abuser alcoholist Prior radiotherapy expect received radiotherapy Unstable uncontrolled cardiac hypertension Other condition opinion investigator preclude enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neutropenia</keyword>
	<keyword>Febrile neutropenia</keyword>
	<keyword>PEG-rhG-CSF</keyword>
	<keyword>Myelosuppressive chemotherapy</keyword>
</DOC>